产品
编 号：F750542
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2249888-53-5
产品详情
生物活性：
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells.
体内研究：
Cevostamab (0.5 mg/kg; i.v.; once weekly for ) suppresses the growth of established MOLP-2 tumors in mice reconstituted with human immune cells.
体外研究：
Cevostamab shows a dose-dependent and robust killing of B cells and bone marrow plasma cells fromperipheral blood mononuclear cell (PBMC)/BMMC samples from cynomolgus monkey.
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells.
体内研究：
Cevostamab (0.5 mg/kg; i.v.; once weekly for ) suppresses the growth of established MOLP-2 tumors in mice reconstituted with human immune cells.
体外研究：
Cevostamab shows a dose-dependent and robust killing of B cells and bone marrow plasma cells fromperipheral blood mononuclear cell (PBMC)/BMMC samples from cynomolgus monkey.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备